Subscribe
istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
15 May 2018Americas

Eli Lilly to acquire cancer drug developer

Eli Lilly has revealed plans to acquire Montreal-based AurKa Pharma, in what is the company’s second acquisition in less than one week.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.

More on this story

Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug